Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q36929502)
Watch
English
Bevacizumab for the treatment of glioblastoma.
scientific article published on 06 June 2013
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PMCID
3682734
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23843722%20AND%20SRC:MED&resulttype=core&format=json
retrieved
5 March 2020
title
Bevacizumab for the treatment of glioblastoma
(English)
1 reference
stated in
Europe PubMed Central
PMCID
3682734
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23843722%20AND%20SRC:MED&resulttype=core&format=json
retrieved
5 March 2020
main subject
bevacizumab
1 reference
based on heuristic
inferred from title
author
Jordi Bruna
series ordinal
4
1 reference
stated in
Europe PubMed Central
PMCID
3682734
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23843722%20AND%20SRC:MED&resulttype=core&format=json
retrieved
5 March 2020
author name string
Miguel J Gil-Gil
series ordinal
1
1 reference
stated in
Europe PubMed Central
PMCID
3682734
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23843722%20AND%20SRC:MED&resulttype=core&format=json
retrieved
5 March 2020
Carlos Mesia
series ordinal
2
1 reference
stated in
Europe PubMed Central
PMCID
3682734
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23843722%20AND%20SRC:MED&resulttype=core&format=json
retrieved
5 March 2020
Montserrat Rey
series ordinal
3
1 reference
stated in
Europe PubMed Central
PMCID
3682734
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23843722%20AND%20SRC:MED&resulttype=core&format=json
retrieved
5 March 2020
language of work or name
English
0 references
publication date
6 June 2013
1 reference
stated in
Europe PubMed Central
PMCID
3682734
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23843722%20AND%20SRC:MED&resulttype=core&format=json
retrieved
5 March 2020
published in
Clinical Medicine Insights: Oncology
1 reference
stated in
Europe PubMed Central
PMCID
3682734
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23843722%20AND%20SRC:MED&resulttype=core&format=json
retrieved
5 March 2020
volume
7
1 reference
stated in
Europe PubMed Central
PMCID
3682734
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23843722%20AND%20SRC:MED&resulttype=core&format=json
retrieved
5 March 2020
page(s)
123-135
1 reference
stated in
Europe PubMed Central
PMCID
3682734
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23843722%20AND%20SRC:MED&resulttype=core&format=json
retrieved
5 March 2020
cites work
Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682734
retrieved
29 September 2017
A phase 3 trial of bevacizumab in ovarian cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682734
retrieved
29 September 2017
Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682734
retrieved
29 September 2017
Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682734
retrieved
29 September 2017
Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682734
retrieved
29 September 2017
Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682734
retrieved
29 September 2017
Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682734
retrieved
29 September 2017
Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682734
retrieved
29 September 2017
Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682734
retrieved
29 September 2017
Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682734
retrieved
29 September 2017
Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682734
retrieved
29 September 2017
Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682734
retrieved
29 September 2017
FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682734
retrieved
29 September 2017
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682734
retrieved
29 September 2017
Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682734
retrieved
29 September 2017
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682734
retrieved
29 September 2017
Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682734
retrieved
29 September 2017
Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682734
retrieved
29 September 2017
Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682734
retrieved
29 September 2017
Safety of anticoagulation use and bevacizumab in patients with glioma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682734
retrieved
29 September 2017
Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682734
retrieved
29 September 2017
The use and toxicity of steroids in the management of patients with brain metastases.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682734
retrieved
29 September 2017
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682734
retrieved
29 September 2017
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682734
retrieved
29 September 2017
Angiogenesis in brain tumours
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682734
retrieved
29 September 2017
The 2007 WHO classification of tumours of the central nervous system
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682734
retrieved
29 September 2017
The pharmacokinetics and pharmacodynamics of monoclonal antibodies--mechanistic modeling applied to drug development.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682734
retrieved
29 September 2017
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682734
retrieved
29 September 2017
Lessons from phase III clinical trials on anti-VEGF therapy for cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682734
retrieved
29 September 2017
Pharmacokinetics of therapeutic monoclonal antibodies used in oncology
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682734
retrieved
29 September 2017
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682734
retrieved
29 September 2017
Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682734
retrieved
29 September 2017
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682734
retrieved
29 September 2017
Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682734
retrieved
29 September 2017
Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682734
retrieved
29 September 2017
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682734
retrieved
29 September 2017
Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682734
retrieved
29 September 2017
The effects of chronic administration of hydrocortisone on cognitive function in normal male volunteers
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682734
retrieved
29 September 2017
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682734
retrieved
29 September 2017
Tumor angiogenesis: therapeutic implications
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682734
retrieved
29 September 2017
What Is the Evidence That Tumors Are Angiogenesis Dependent?
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682734
retrieved
29 September 2017
Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682734
retrieved
27 June 2018
Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO).
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682734
retrieved
4 September 2018
AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682734
retrieved
4 September 2018
Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682734
retrieved
4 September 2018
Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682734
retrieved
4 September 2018
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682734
retrieved
4 September 2018
Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682734
retrieved
4 September 2018
Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682734
retrieved
4 September 2018
Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682734
retrieved
4 September 2018
Clinical pharmacokinetics of bevacizumab in patients with solid tumors.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682734
retrieved
4 September 2018
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682734
retrieved
4 September 2018
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682734
retrieved
4 September 2018
Autocrine pathways of the vascular endothelial growth factor (VEGF) in glioblastoma multiforme: clinical relevance of radiation-induced increase of VEGF levels.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682734
retrieved
4 September 2018
Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3682734
retrieved
4 September 2018
Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/23843722
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Identifiers
DOI
10.4137/CMO.S8503
1 reference
stated in
Europe PubMed Central
PMCID
3682734
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23843722%20AND%20SRC:MED&resulttype=core&format=json
retrieved
5 March 2020
PMCID
3682734
1 reference
stated in
Europe PubMed Central
PMCID
3682734
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23843722%20AND%20SRC:MED&resulttype=core&format=json
retrieved
5 March 2020
PubMed ID
23843722
1 reference
stated in
Europe PubMed Central
PMCID
3682734
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23843722%20AND%20SRC:MED&resulttype=core&format=json
retrieved
5 March 2020
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
